Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04858776 · ClinicalTrials.gov registry record · Phase 2
Perivenous Dexamethasone Therapy: Examining Reduction of Inflammation After Thrombus Removal to Yield Benefit in Subacute and Chronic Iliofemoral DVT
A Phase 2 study of Iliofemoral; Thrombosis, sponsored by Mercator MedSystems.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 15
- Study locations
NCT04858776: Recruiting Phase 2 study of Iliofemoral; Thrombosis, sponsored by Mercator MedSystems.
NCT04858776 is a Phase 2 study of Iliofemoral; Thrombosis that is actively recruiting participants, run by Mercator MedSystems. The registered enrollment target is 60 participants. The trial reports 15 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04858776, a Phase 2 study of Iliofemoral; Thrombosis, is actively recruiting participants, sponsored by Mercator MedSystems.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 15
- Study locations
Study Summary
This is a study of a medical procedure that utilizes a commercially available catheter (the Bullfrog® Micro-Infusion Device) to locally deliver a commercially available anti-inflammatory drug (dexamethasone sodium phosphate injection) around the deep veins after DVT recanalization, where DVT symptoms were present for at least 14 days and no more than 60 days prior to recanalization. The goal of the study is to see if local anti-inflammation helps prevent re-thrombosis of the blood vessel and improvement in symptoms for up to 24 months after the initial DVT recanalization procedure.
Conditions Studied
Interventions
- COMBINATION_PRODUCT Perivascular dexamethasone
- COMBINATION_PRODUCT Perivascular sham
Study Locations (15)
Texas
- CardioVoyage - Denison
- University of Texas, Houston - Houston
Other
- Galway University Hospital - Galway
- Guy's and St. Thomas Hospital - London
Connecticut
- Vascular Care Connecticut - Darien
Florida
- University of South Florida - Tampa
Illinois
- Northwestern University Hospital - Chicago
Louisiana
- CIS Clinical Research - Houma
Maryland
- Medstar Health Research Institute - Hyattsville
New York
- Stony Brook University Hospital - Stony Brook
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2022-08-08 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04858776
The ClinicalTrials.gov registry entry for NCT04858776 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mercator MedSystems, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Iliofemoral; Thrombosis appearing as the primary indexed condition, and to 2 interventions - of which Perivascular dexamethasone is the first listed.
NCT04858776 reports 15 study locations spanning 13 distinct geographic areas - top geographies include Texas, Other, Connecticut.
Frequently Asked Questions
What is clinical trial NCT04858776 about?
NCT04858776 is a clinical study titled "Perivenous Dexamethasone Therapy: Examining Reduction of Inflammation After Thrombus Removal to Yield Benefit in Subacute and Chronic Iliofemoral DVT". This is a study of a medical procedure that utilizes a commercially available catheter (the Bullfrog® Micro-Infusion Device) to locally deliver a commercially available anti-inflammatory drug (dexamethasone sodium phosphate injection) around the deep veins after DVT recanalization, where DVT symptom...
What is the current status of trial NCT04858776?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2022-08-08. Estimated completion is 2026-12-31.
What conditions does trial NCT04858776 study?
This clinical trial studies the following conditions: Iliofemoral; Thrombosis.
What interventions are being tested in trial NCT04858776?
The interventions under investigation include: Perivascular dexamethasone (COMBINATION_PRODUCT), Perivascular sham (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT04858776?
This trial is sponsored by Mercator MedSystems, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04858776 being conducted?
This trial has 15 study locations across Connecticut, Florida, Illinois, Louisiana, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Iliofemoral; Thrombosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.